David, Anna L. http://orcid.org/0000-0002-0199-6140
Ahmadzia, Homa http://orcid.org/0000-0003-0341-1086
Ashcroft, Richard http://orcid.org/0000-0001-6065-4717
Bucci-Rechtweg, Christina http://orcid.org/0000-0003-1250-9931
Spencer, Rebecca N. http://orcid.org/0000-0002-3019-0322
Thornton, Steve http://orcid.org/0000-0001-7613-0408
Funding for this research was provided by:
UCLH Biomedical Research Centre
National Institutes of Health
Research Trainees Coordinating Centre
British Heart Foundation
Barts and The London School of Medicine and Dentistry
Article History
Received: 21 February 2022
Accepted: 30 June 2022
First Online: 25 July 2022
Declarations
:
: ALD receives consulting fees from Esperare Foundation, Geneva, Switzerland, a private not-for-profit advising on the development of an investigational fetal drug therapy. She is an unpaid co-Chair of the Maternal Health Project Group of the Association of British Pharmaceutical Industry (ABPI). HA has agreed to serve as a consultant for Coagulant Therapeutics. CBR is a fulltime employee of and receives restricted stock units from Novartis Pharmaceuticals Corporation. RS and RA have no financial interests to disclose. ST is Interim managing director of UCLPartners and Vice Principal at Queen Mary. He has received commercial income for work related to preterm birth. He has undertaken consultancies (including GSK) and received income. He is a Trustee of the Royal College of Obstetricians and Gynaecologists, MedCity and the William Harvey Research Foundation.